Immune-Related Colitis and Fulminant Hepatitis Following Immune Checkpoint Inhibitor-Based Combination Therapy in Hepatocellular Carcinoma: Two Case Reports
Convergence Hepatology · 31.05.2026 · 2 (1) · 79-87
DOI: 10.65633/ch.2026.2.1.79 ↗Kurz gefasst
Fachartikel in der Zeitschrift Convergence Hepatology, erschienen am 31.05.2026. Verfasst von Young Joo Park und 3 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Pusan National University Hospital.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the treatment of advanced hepatocellular carcinoma (HCC), yet immune-related adverse events (irAEs) remain a serious and potentially fatal complication. We report two cases of severe irAEs following ICIbased therapy for HCC. In Case 1, a man with multimetastatic HCC developed immune-mediated colitis with hemodynamic collapse and multi-organ failure after the second cycle of the STRIDE regimen yet achieved a near-complete oncologic response. In Case 2, a patient who had tolerated 17 cycles of adjuvant atezolizumab (ate) plus bevacizumab (bev) without irAE developed fatal immune-mediated fulminant hepatitis after a single dose of ate+bev reinitiated as first-line therapy for unresectable HCC following recurrence and TACE failure. These cases highlight the unpredictability of irAEs—even in previously tolerant patients—and underscore the importance of early recognition and prompt management.
Förderung
- Pusan National University Hospital
Zitieren
APA
Park, Y. J., Yi, K., Woo, H. Y., & Heo, J. (2026). Immune-Related Colitis and Fulminant Hepatitis Following Immune Checkpoint Inhibitor-Based Combination Therapy in Hepatocellular Carcinoma: Two Case Reports. Convergence Hepatology, 2(1), 79-87. https://doi.org/10.65633/ch.2026.2.1.79
Vancouver
Park YJ, Yi K, Woo HY, Heo J. Immune-Related Colitis and Fulminant Hepatitis Following Immune Checkpoint Inhibitor-Based Combination Therapy in Hepatocellular Carcinoma: Two Case Reports. Convergence Hepatology. 2026;2(1):79-87. doi:10.65633/ch.2026.2.1.79
BibTeX
@article{Park2026,
author = {Park, Young Joo and Yi, Kiyoun and Woo, Hyun Young and Heo, Jeong},
title = {Immune-Related Colitis and Fulminant Hepatitis Following Immune Checkpoint Inhibitor-Based Combination Therapy in Hepatocellular Carcinoma: Two Case Reports},
journal = {Convergence Hepatology},
year = {2026},
volume = {2},
number = {1},
pages = {79--87},
doi = {10.65633/ch.2026.2.1.79}
}
EUVIMED